Reports
Sale
Autism Spectrum Disorder Therapeutics Market Size, Share: By Disease Type: Autistic Disorder, Asperger’s Syndrome, Pervasive Development Disorder (PDD), Others; By Treatment Type: Antipsychotic Drugs, Others; By Age Group; By Route of Administration; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
Autism Spectrum Disorder Therapeutics Market Size
The autism spectrum disorder therapeutics market size attained a value of USD 2.11 billion in 2023, driven by the increasing research and development aided by the government and industrial players, and a growing pipeline of autism spectrum disorder drugs across the 8 major markets. The market is anticipated to grow at a CAGR of 6.10% during the forecast period of 2024-2032 to attain a value of USD 3.56 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Autism Spectrum Disorder Therapeutics Market Outlook
- Increased funding and support for autism spectrum disorder research and treatment development is shaping the market dynamics.
- One of the major market trends is the rising advancement in diagnostic tools that enable early detection of autism spectrum disorder and ensure timely intervention.
- The surge in clinical research activities associated with autism spectrum disorder is expected to result in the introduction of new and effective treatment options in the forecast period.
Autism Spectrum Disorder Therapeutics Market Overview
Autism spectrum disorder (ASD) is a neurological development disability characterized by conditions such as anxiety, depression, and attention-deficit, hyperactivity, among others. This neurological and developmental disorder can begin in infancy and last throughout adulthood throughout a person’s life. It can be diagnosed based on behavioural patterns. ASD treatments are focused on reducing the factors that interfere with an individual’s orderly functioning. Some of the drugs approved by the U.S. FDA include Risperidone and Aripiprazole for treating irritability associated with ASD.
The autism spectrum disorder therapeutics market is affected by the growing number of patients and the increasing awareness regarding the disease. The rising governmental initiatives are also expected to encourage research in this area. Further, rapid technological advancements in medicine are likely to favor market growth during the forecast period. Moreover, the adoption of behavioral therapies to overcome the communication gap in such patients is poised to aid the market expansion.
Autism Spectrum Disorder Therapeutics Market Growth Drivers
Rising Number of Pipeline Drugs Expected to Propel Market Growth
The forecast period is expected to witness rising development of drugs to treat autism spectrum disorder. The presence of a growing pipeline of ASD drugs and increasing research and development in this field is expected to boost the market growth. For instance, in 2023, STALICLA, a Swiss clinical-stage biotech company announced the completion of the phase 1b trials for STP1. The trials will allow the application of the company’s precision medicine discovery platform in ASD. The increasing research and development activities associated with autism spectrum disorder are expected to result in the introduction of new and effective treatment options, which are set to elevate the market value.
Growth in Clinical Trials to Meet Rising Autism Spectrum Disorder Therapeutics Market Demand
In March 2024, a clinical-stage biopharmaceutical company based in Israel, SciSparc Ltd., announced the dosing of the first patient in the SCI-210 clinical trial, a randomized, controlled, double-blind clinical trial for pediatric patients with autism spectrum disorder. SCI-210 treatment is a combination of CannAmide™ (palmitoylethanolamide-based tablets) and cannabidiol-rich oil (CBD). The clinical trial, which will enroll 60 children, aims to assess the safety, efficacy, and tolerability of SCI-210 for the treatment of ASD in comparison to CBD monotherapy. The surge in clinical trials, supported by substantial investment from the leading pharmaceutical companies, is anticipated to significantly contribute to the market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Autism Spectrum Disorder Therapeutics Market Trends
The market is witnessing several trends and developments to improve the current scenario across the 8 major markets. Some of the notable trends are as follows:
| Key Trends | Impact |
| Advancement in Diagnostic Tools | The rising advancement in diagnostic tools and techniques that enable earlier detection of autism spectrum disorder is a major trend that stimulates the demand for the therapeutics market. Further, increased implementation of screening programs, particularly in schools and pediatric practices, is resulting in early diagnosis and timely intervention. |
| Development of Behavioral Therapies | The rising focus on the development of behavioral therapies is a major market trend. Behavioral therapies including applied behavior analysis (ABA) and cognitive-behavioral therapy (CBT) are increasingly being integrated into treatment plans and are poised to boost the autism spectrum disorder therapeutics market share. |
| Rising Adoption of Telemedicine and Digital Health Platforms | The market is experiencing a rising adoption of telemedicine and digital health platforms which has expanded access to care for individuals with autism spectrum disorder, particularly those living in underserved areas. The increasing remote access to care is expected to augment the market demand in the forecast period. |
| Increased Awareness Campaigns | Increased public campaigns and advocacy efforts are leading to greater acceptance of autism spectrum disorder, which is resulting in early diagnosis of the affected patients. In addition, advocacy groups and several foundations are offering considerable funding and support for ASD research and treatment development, which directly impacts the market dynamics. |
Autism Spectrum Disorder Therapeutics Market Segmentation
Market Breakup by Disease Type
- Autistic Disorder
- Asperger’s Syndrome
- Pervasive Development Disorder (PDD)
- Others
Market Breakup by Treatment Type
- Antipsychotic Drugs
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Stimulants
- Sleep Medications
- Others
Market Breakup by Age Group
- Child
- Adult
Market Breakup by Route of Administration
- Oral
- Parenteral
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Autism Spectrum Disorder Therapeutics Market Share
Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth
Based on treatment, the market is segmented into antipsychotic drugs, selective serotonin reuptake inhibitors (SSRIs), stimulants, and sleep medications, among others. These medications help in treating different aspects associated with the disorder, ranging from managing core symptoms to treating comorbid conditions. The antipsychotic drugs segment covers a significant market share owing to their efficacy in managing severe behavioral issues such as aggression, irritability, and self-injurious behaviors, which are common in individuals affected by the condition.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Autism Spectrum Disorder Therapeutics Market Analysis by Region
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is expected to hold a significant share of the market during the forecast period, supported by the increased number of autism spectrum disorder cases in the region. The market is also supported by the presence of a favorable regulatory environment. For example, the United States Food and Drug Administration (FDA) authorized the marketing of Cognoa ASD Diagnosis Aid, a device to help diagnose autism spectrum disorder (ASD) in 2021.
The region is also characterised by research and development in the field of autism spectrum disorder which is expected to propel market growth during the forecast period. For instance, the National Institute of Mental Health headquartered in the United States, supports research focused on the treatment of autism spectrum disorder and related disorders.
Leading Players in the Autism Spectrum Disorder Therapeutics Market
The key features of the market report comprise patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Abbvie Inc.
American pharmaceutical company AbbVie Inc. is involved in research and development (R&D) efforts to create medications for autism spectrum disorder. The company's robust portfolio of neurological and psychiatric therapeutics and its strong R&D capabilities position it as a significant player in the market.
Jazz Pharmaceuticals
This global biopharmaceutical company specializes in developing treatments in the neuroscience and oncology domain. Jazz Pharmaceuticals plays a crucial role in driving innovation and growth in the market by substantially investing in the clinical development of ASD therapeutics.
Novartis AG
Novartis AG, a Swiss multinational pharmaceutical corporation, significantly contributes to autism spectrum disorder therapeutics market growth, by participating in strategic collaborations to advance the understanding and treatment of ASD. Such partnerships also accelerate the development of effective therapies.
Johnson & Johnson Services, Inc.
Johnson & Johnson pharmaceutical drug division Johnson & Johnson Innovative Medicine heavily invests in research and development for neurological disorders including autism spectrum disorder. Its established portfolio of psychiatric medications makes it one of the leading players in the market.
Other key players in the market include Curemark LLC, Bristol Myers Squibb Co., Axial Therapeutics, Q BioMed Inc., PaxMedica, Otsuka Pharmaceutical, Stalicla SA, and Zynerba Pharmaceuticals, Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Treatment Type |
|
| Breakup by Age Group |
|
| Breakup by Route of Administration |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Autism Spectrum Disorder Therapeutics Market Report
- What was the autism spectrum disorder therapeutics market value in 2023?
- What is the autism spectrum disorder therapeutics market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on disease type?
- What is the market breakup based on treatment type?
- What is the market breakup by age group?
- What is market segmentation based on the route of administration?
- What are the major factors aiding the autism spectrum disorder therapeutics market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence and incidence of autism spectrum disorder affect the market landscape?
- What are the major autism spectrum disorder therapeutics market trends?
- Which disease type will dominate the market share?
- Which treatment type is expected to have a high market value in the coming years?
- Which route of administration will experience the highest demand in the market segment?
- Which age group is projected to contribute to the highest market growth?
- Who are the key players involved in the autism spectrum disorder therapeutics market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Autism Spectrum Disorder Therapeutics Market Overview: 8 Major Market
3.1 Autism Spectrum Disorder Therapeutics Market Historical Value (2017-2023)
3.2 Autism Spectrum Disorder Therapeutics Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Autism: Disease Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Therapy Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Therapy Success Rate
7 Autism Spectrum Disorder Therapeutics Market Epidemiology Scenario and Forecast – 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2017-2032)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 U.K.
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Mortality by Country
7.1.2.1 U.S.
7.1.2.2 U.K.
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate by Country
7.1.3.1 U.S.
7.1.3.2 U.K.
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Autism Spectrum Disorder Therapeutics Market Landscape: 8 Major Market*
8.1 Autism Spectrum Disorder Therapeutics Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Autism Spectrum Disorder Therapeutics Market: Product Landscape
8.2.1 Analysis by Disease Type
8.2.2 Analysis by Treatment Type
8.2.3 Analysis by Age Group
8.2.4 Analysis by Route of Administration
9 Autism Spectrum Disorder Therapeutics Market Therapy Challenges and Unmet Needs
9.1 Therapy Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Therapy
11 Autism Spectrum Disorder Therapeutics: Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Autism Spectrum Disorder Therapeutics Market Segmentation: 8 Major Market
12.1 Autism Spectrum Disorder Therapeutics Market by Disease Type
12.1.1 Market Overview
12.1.2 Autistic Disorder
12.1.3 Asperger’s Syndrome
12.1.4 Pervasive Development Disorder (PDD)
12.1.5 Others
12.2 Autism Spectrum Disorder Therapeutics Market by Treatment Type
12.2.1 Market Overview
12.2.2 Antipsychotic Drugs
12.2.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
12.2.4 Stimulants
12.2.5 Sleep Medications
12.2.6 Others
12.3 Autism Spectrum Disorder Therapeutics Market by Age Group
12.3.1 Market Overview
12.3.2 Child
12.3.3 Adult
12.4 Autism Spectrum Disorder Therapeutics Market by Route of Administration
12.4.1 Market Overview
12.4.2 Oral
12.4.3 Parenteral
12.5 Autism Spectrum Disorder Therapeutics Market by Region
12.5.1 Market Overview
12.5.2 United States
12.5.3 EU-4 and the United Kingdom
12.5.3.1 Germany
12.5.3.2 France
12.5.3.3 Italy
12.5.3.4 Spain
12.5.3.5 United Kingdom
12.5.4 Japan
12.5.5 India
13 United States Autism Spectrum Disorder Therapeutics Market (2017-2032)
13.1 United States Autism Spectrum Disorder Therapeutics Market Historical Value (2017-2023)
13.2 United States Autism Spectrum Disorder Therapeutics Market Forecast Value (2024-2032)
13.3 United States Autism Spectrum Disorder Therapeutics Market by Disease Type
13.3.1 Market Overview
13.3.2 Autistic Disorder
13.3.3 Asperger’s Syndrome
13.3.4 Pervasive Development Disorder (PDD)
13.3.5 Others
13.4 United States Autism Spectrum Disorder Therapeutics Market by Treatment Type
13.4.1 Market Overview
13.4.2 Antipsychotic Drugs
13.4.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
13.4.4 Stimulants
13.4.5 Sleep Medications
13.4.6 Others
13.5 United States Autism Spectrum Disorder Therapeutics Market by Age Group
13.5.1 Market Overview
13.5.2 Child
13.5.3 Adult
13.6 United States Autism Spectrum Disorder Therapeutics Market by Route of Administration
13.6.1 Market Overview
13.6.2 Oral
13.6.3 Parenteral
14 EU-4 and United Kingdom Autism Spectrum Disorder Therapeutics Market (2017-2032)
14.1 EU-4 and United Kingdom Autism Spectrum Disorder Therapeutics Market Historical Value (2017-2023)
14.2 EU-4 and United Kingdom Autism Spectrum Disorder Therapeutics Market Forecast Value (2024-2032)
14.3 EU-4 and United Kingdom Autism Spectrum Disorder Therapeutics Market by Disease Type
14.3.1 Market Overview
14.3.2 Autistic Disorder
14.3.3 Asperger’s Syndrome
14.3.4 Pervasive Development Disorder (PDD)
14.3.5 Others
14.4 EU-4 and United Kingdom Autism Spectrum Disorder Therapeutics Market by Treatment Type
14.4.1 Market Overview
14.4.2 Antipsychotic Drugs
14.4.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
14.4.4 Stimulants
14.4.5 Sleep Medications
14.4.6 Others
14.5 EU-4 and United Kingdom Autism Spectrum Disorder Therapeutics Market by Age Group
14.5.1 Market Overview
14.5.2 Child
14.5.3 Adult
14.6 EU-4 and United Kingdom Autism Spectrum Disorder Therapeutics Market by Route of Administration
14.6.1 Market Overview
14.6.2 Oral
14.6.3 Parenteral
15 Japan Autism Spectrum Disorder Therapeutics Market
15.1 Japan Autism Spectrum Disorder Therapeutics Market Historical Value (2017-2023)
15.2 Japan Autism Spectrum Disorder Therapeutics Market Forecast Value (2024-2032)
15.3 Japan Autism Spectrum Disorder Therapeutics Market by Disease Type
15.3.1 Market Overview
15.3.2 Autistic Disorder
15.3.3 Asperger’s Syndrome
15.3.4 Pervasive Development Disorder (PDD)
15.3.5 Others
15.4 Japan Autism Spectrum Disorder Therapeutics Market by Treatment Type
15.4.1 Market Overview
15.4.2 Antipsychotic Drugs
15.4.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
15.4.4 Stimulants
15.4.5 Sleep Medications
15.4.6 Others
15.5 Japan Autism Spectrum Disorder Therapeutics Market by Age Group
15.5.1 Market Overview
15.5.2 Child
15.5.3 Adult
15.6 Japan Autism Spectrum Disorder Therapeutics Market by Route of Administration
15.6.1 Market Overview
15.6.2 Oral
15.6.3 Parenteral
16 India Autism Spectrum Disorder Therapeutics Market
16.1 India Autism Spectrum Disorder Therapeutics Market (2017-2032) Historical Value (2017-2023)
16.2 India Autism Spectrum Disorder Therapeutics Market (2017-2032) Forecast Value (2024-2032)
16.3 India Autism Spectrum Disorder Therapeutics Market by Disease Type
16.3.1 Market Overview
16.3.2 Autistic Disorder
16.3.3 Asperger’s Syndrome
16.3.4 Pervasive Development Disorder (PDD)
16.3.5 Others
16.4 India Autism Spectrum Disorder Therapeutics Market by Treatment Type
16.4.1 Market Overview
16.4.2 Antipsychotic Drugs
16.4.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
16.4.4 Stimulants
16.4.5 Sleep Medications
16.4.6 Others
16.5 India Autism Spectrum Disorder Therapeutics Market by Age Group
16.5.1 Market Overview
16.5.2 Child
16.5.3 Adult
16.6 India Autism Spectrum Disorder Therapeutics Market by Route of Administration
16.6.1 Market Overview
16.6.2 Oral
16.6.3 Parenteral
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 INDIA CDSCO
17.5 JAPAN PMDA
17.6 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Clinical Trial Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Grant Analysis
20.1 Analysis by Year
20.2 Analysis by Amount Awarded
20.3 Analysis by Issuing Authority
20.4 Analysis by Grant Product
20.5 Analysis by Funding Institute
20.6 Analysis by Departments
20.7 Analysis by Recipient Organization
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Strategic Initiatives
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Market Share by Top 5 Companies
23.2 Abbvie Inc
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Jazz Pharmaceuticals
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Novartis AG
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Johnson & Johnson Services, Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Curemark LLC
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Bristol Myers Squibb Co .
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Axial therapeutics
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Q BioMed Inc .
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 PaxMedica
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Otsuka Pharmaceutica
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Stalicla SA
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Zynerba Pharmaceuticals, Inc .
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
24 Autism Spectrum Disorder Therapeutics Market – Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER